E-Newsletter - September 2022
Upcoming Group Meeting
ALLIANCE fall hybrid GROUP MEETING CONVENES november 2-5
The Alliance for Clinical Trials in Oncology will convene its 2022 Fall Hybrid Group Meeting in Chicago November 2-5. This will be the second hybrid meeting where members and guests can attend either in-person or virtually. Scientists, clinical research professionals, patient advocates and others interested in the latest developments in cancer research are expected to participate in the four-day meeting held at the Loews Chicago O'Hare Hotel. Meeting attendees will select from nearly 100 disease, modality, administrative and special sessions to attend led by distinguished oncology researchers and clinical trial specialists from across the country. This meeting will showcase novel and innovative cancer control, prevention, and treatment trials that are conducted by investigators through a multidisciplinary academic and community research network, which is part of the NCI National Clinical Trials Network (NCTN) and Community Oncology Research Program (NCORP).
View the MEETING SCHEDULE and REGISTER today.
Remember: sessions listed as closed are only open to official committee members and invited guests.
Registration must be completed to gain access to the Zoom information in the meeting app.
For questions about the Group meeting, contact AllianceTravel@bwh.harvard.edu.
Read more articles in this month's e-newsletter:
- Alliance Leadership Transition: Suzanne George, MD, Appointed Interim Group Chair
- Alliance Welcomes Three New Patient Advocates
-
October is National Breast Cancer Awareness Month
A011801 (COMPASS HER2 RD/Breast Cancer)
A071701 (Genomically-guided Treatment in Brain Metastases)
A191901 (Optimizing Endocrine Therapy)
A221803 (Reducing Radiation Dermatitis)
A231910CD (Patient-centered Communication in Breast Cancer) -
Spotlight on Alliance Trials
*Recently Activated Trials
A212102 (Multicancer Early Detection Blood Tests)
A032101 (Metastatic Hormone-sensitive Prostate Cancer)
*Ongoing Trials
A032002 (Metastatic Urothelial Cancer)
A051902 (Peripheral T-cell Lymphoma)
A081801 (Resected Non-small Cell Lung Cancer)
A222001 (Hot Flashes in Men/Androgen Deprivation Therapy) -
Announcements
Registration Now Open: 2022 Alliance Fall Hybrid Group Meeting
Call for Applications: Alliance CRP Committee Cadre Members
Call for Proposals: Alliance Cancer Control Program Pilot Awards -
Alliance in the News
Alliance for Clinical Trials in Oncology Applauds Appointment of Monica M. Bertagnolli as NCI's New Director
Interview with Patient on Alliance RadiCaL Study (A031801)
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
Novel Drug Delivery Systems for Patients With Advanced Prostate Cancer: A Focus on Radioligand Therapy and ADCs
Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated with Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial
Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance)
Preoperative Combination Chemotherapy Improved Survival in Patients with Pancreatic Cancer
Alliance Foundation Trials Study Finds Combination Hormonal Therapy Delivered in Finite Period Improves PSA Levels in Patients with Prostate Cancer
Alliance MCED Biobank Study May Provide Greater Understanding of How to Detect Multiple Cancers